A Systematic Review of Apremilast as a Therapeutic Option for Lichen Planus.
Priyanka Hemrajani, Anmol Godara, Arushi Ghosh et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the efficacy and safety of apremilast in treating lichen planus (LP) across 17 patients from six studies. The findings indicate that 41% of patients achieved remission, particularly among those with oral LP. The study highlights the potential of apremilast as a monotherapy, though it notes the need for further research due to small sample size and limited follow-up.
Key findings
- 41% of patients achieved remission, including 33% of those with oral LP.
- 71% of the patients were female, with oral LP being the most common subtype at 88%.
- Disease progression was the major reason for treatment discontinuation in 29% of patients.
- No life-threatening adverse effects were reported during the study.
Why it matters
Understanding the efficacy and safety of apremilast for lichen planus can guide clinicians in selecting treatment options, especially for patients who have not responded to other therapies. This review provides insights into patient demographics and treatment outcomes.
What to keep in mind
The review is limited by a small sample size and heterogeneity in dosing and treatment duration.